Cargando…

Ivermectin, a potential anticancer drug derived from an antiparasitic drug

Ivermectin is a macrolide antiparasitic drug with a 16-membered ring that is widely used for the treatment of many parasitic diseases such as river blindness, elephantiasis and scabies. Satoshi ōmura and William C. Campbell won the 2015 Nobel Prize in Physiology or Medicine for the discovery of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Mingyang, Hu, Xiaodong, Wang, Yi, Yao, Xin, Zhang, Wei, Yu, Chenying, Cheng, Fuying, Li, Jiangyan, Fang, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505114/
https://www.ncbi.nlm.nih.gov/pubmed/32971268
http://dx.doi.org/10.1016/j.phrs.2020.105207
_version_ 1783584751873949696
author Tang, Mingyang
Hu, Xiaodong
Wang, Yi
Yao, Xin
Zhang, Wei
Yu, Chenying
Cheng, Fuying
Li, Jiangyan
Fang, Qiang
author_facet Tang, Mingyang
Hu, Xiaodong
Wang, Yi
Yao, Xin
Zhang, Wei
Yu, Chenying
Cheng, Fuying
Li, Jiangyan
Fang, Qiang
author_sort Tang, Mingyang
collection PubMed
description Ivermectin is a macrolide antiparasitic drug with a 16-membered ring that is widely used for the treatment of many parasitic diseases such as river blindness, elephantiasis and scabies. Satoshi ōmura and William C. Campbell won the 2015 Nobel Prize in Physiology or Medicine for the discovery of the excellent efficacy of ivermectin against parasitic diseases. Recently, ivermectin has been reported to inhibit the proliferation of several tumor cells by regulating multiple signaling pathways. This suggests that ivermectin may be an anticancer drug with great potential. Here, we reviewed the related mechanisms by which ivermectin inhibited the development of different cancers and promoted programmed cell death and discussed the prospects for the clinical application of ivermectin as an anticancer drug for neoplasm therapy.
format Online
Article
Text
id pubmed-7505114
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-75051142020-09-23 Ivermectin, a potential anticancer drug derived from an antiparasitic drug Tang, Mingyang Hu, Xiaodong Wang, Yi Yao, Xin Zhang, Wei Yu, Chenying Cheng, Fuying Li, Jiangyan Fang, Qiang Pharmacol Res Review Ivermectin is a macrolide antiparasitic drug with a 16-membered ring that is widely used for the treatment of many parasitic diseases such as river blindness, elephantiasis and scabies. Satoshi ōmura and William C. Campbell won the 2015 Nobel Prize in Physiology or Medicine for the discovery of the excellent efficacy of ivermectin against parasitic diseases. Recently, ivermectin has been reported to inhibit the proliferation of several tumor cells by regulating multiple signaling pathways. This suggests that ivermectin may be an anticancer drug with great potential. Here, we reviewed the related mechanisms by which ivermectin inhibited the development of different cancers and promoted programmed cell death and discussed the prospects for the clinical application of ivermectin as an anticancer drug for neoplasm therapy. Elsevier Ltd. 2021-01 2020-09-21 /pmc/articles/PMC7505114/ /pubmed/32971268 http://dx.doi.org/10.1016/j.phrs.2020.105207 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Tang, Mingyang
Hu, Xiaodong
Wang, Yi
Yao, Xin
Zhang, Wei
Yu, Chenying
Cheng, Fuying
Li, Jiangyan
Fang, Qiang
Ivermectin, a potential anticancer drug derived from an antiparasitic drug
title Ivermectin, a potential anticancer drug derived from an antiparasitic drug
title_full Ivermectin, a potential anticancer drug derived from an antiparasitic drug
title_fullStr Ivermectin, a potential anticancer drug derived from an antiparasitic drug
title_full_unstemmed Ivermectin, a potential anticancer drug derived from an antiparasitic drug
title_short Ivermectin, a potential anticancer drug derived from an antiparasitic drug
title_sort ivermectin, a potential anticancer drug derived from an antiparasitic drug
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505114/
https://www.ncbi.nlm.nih.gov/pubmed/32971268
http://dx.doi.org/10.1016/j.phrs.2020.105207
work_keys_str_mv AT tangmingyang ivermectinapotentialanticancerdrugderivedfromanantiparasiticdrug
AT huxiaodong ivermectinapotentialanticancerdrugderivedfromanantiparasiticdrug
AT wangyi ivermectinapotentialanticancerdrugderivedfromanantiparasiticdrug
AT yaoxin ivermectinapotentialanticancerdrugderivedfromanantiparasiticdrug
AT zhangwei ivermectinapotentialanticancerdrugderivedfromanantiparasiticdrug
AT yuchenying ivermectinapotentialanticancerdrugderivedfromanantiparasiticdrug
AT chengfuying ivermectinapotentialanticancerdrugderivedfromanantiparasiticdrug
AT lijiangyan ivermectinapotentialanticancerdrugderivedfromanantiparasiticdrug
AT fangqiang ivermectinapotentialanticancerdrugderivedfromanantiparasiticdrug